Betamethasone Sodium Phosphate & Betamethasone Acetate* Injectable Suspension, USP

Please see reverse side for Important Safety Information

Dual- agent

Corticosteroid

Fast-Acting Long-Lasting

BetamethasoneSodium Phosphate &

Betamethasone Acetate* Injectable Suspension, USP

Kenalog® (Triamcinolone Acetonide) Injectable Suspension, USP

Depo-Medrol® (Methylprednisolone Acetate Injectable Suspension, USP)

PP

PX

PX

Kenalog® is a registered trademark of Bristol-Myers Squibb. Depo-Medrol® is a registered trademark of Pfizer Inc.

Product Name

FAST-ACTING& LONG-LASTING

®

Strength Size Shelf Pack McKesson Item #

Cardinal Item #

Amerisource-Bergen Item #

6 mg/mL (3 mg/mL Betamethasone

Sodium Phosphate and 3 mg/mL Betamethasone Acetate*)

5 mL Multiple

Dose Vial 19731301 4299483 080061

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate* Injectable Suspension, USP is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. Please see reverse side for Important Safety Information and Full Prescribing Information enclosed in pocket.

A Dual-Agent Corticosteroid for Painful Inflammatory Conditions

Betamethasone Has One of the Highest Anti-Inflammatory Potencies per mg†

†Comparison of anti-inflammatory potency only; no suggestion of superior efficacy or safety intended

**These dose relationships apply only to oral or intravenous administration of these compounds. When these substances are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.

Free Ester Glucocorticoid Preparations†

Anti-Inflammatory Equivalent Dose Sodium-Retaining Plasma Half-life Biologic Half-life Potency (mg)** Potency (min) (hr)

Cortisone 0.8 25 2+ 30 8 – 12

Hydrocortisone 1 20 2+ 90 8 – 12

Prednisone 4 5 1+ 60 12 – 36

Methylprednisolone 5 4 0 180 12 – 36

Triamcinolone 5 4 0 300 12 – 36

Betamethasone 20 – 30 0.75 0 100 – 300 36 – 54

• Begins to reduce inflammation in 1-2 hours• Provides sustained relief• High anti-inflammatory potency†

• Minimal sodium-retaining potency• Long plasma & biological half-life

Your patients don’t need to wait hours for relief!

NDC 0517- 0720-01 HCPCS “J” Code: J0702

Recommended Doses for Intra-articular injection of Betamethasone Sodium Phosphate & Betamethasone Acetate*

Size of Joint Location Dose (mL)Very Large Hip 1 – 2Large Knee, Ankle, Shoulder 1Medium Elbow, Wrist 0.5 – 1Small Hand, Chest 0.25 – 0.5(metacarpophalangeal, interphalangeal, sternoclavicular)

A portion of the administered dose of Betamethasone Sodium Phosphate and Betamethasone Acetate* Injectable Suspension is absorbed systemically following intra-articular injection. In patients being treated concomitantly with oral or parenteral cort-costeroids, especially those receiving large doses, the systemic absorption of the drug should be considered in determining intra-articular dosage. For additional dosing information please refer to package insert.

Betamethasone Sodium Phosphate& Betamethasone Acetate*Injectable Suspension, USP*Betamethasone 6 mg/mL as 3 mg/mL Betamethasone Sodium Phosphate and 3 mg/mL Betamethasone Acetate

Celestone® and Soluspan® are registered trademarks of Schering Corp.

The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Important Safety Information

Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.

As with any potent corticosteroid, adverse events have been associated with Betamethasone Sodium Phosphate and Betamethasone Acetate, Injectable Suspension, USP including fluid and electrolyte disturbances, as well as adverse reactions involving the following systems: allergic reactions, cardiovascular, dermatologic, endocrine, gastrointestinal, metabolic, musculoskeletal, neurological/psychiatric, ophthalmic and other. Corticosteroids may also affect immune response. Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy.

Betamethasone Sodium Phosphate and Betamethasone Acetate, Injectable Suspension, USP should not be administered intravenously or used in systemic fungal infections. Vaccination administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.

Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop fever or other signs of infections. Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or measles and to seek medical advice without delay if exposed.

Please see Full Prescribing Information enclosed in pocket

BB033 Rev. 8/2014

®

One Luitpold Drive - PO Box 9001 - Shirley, NY 11967 | 800-645-1706 | www.DualAgentBeta.com

• First and only AB-rated, therapeutically-equivalent generic to Celestone® Soluspan®

• NDC 0517-0720-01• J Code 0702